KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING
SYDNEY, Dec. 15, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with QIMR Berghofer Medical Research Institute, one of Australia’s foremost cancer research centres, to explore…
Comments Off on KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING